Patient Resources
Mobile Administration Program (MAP)
This program offers administration of Sandostatin® LAR Depot (octreotide acetate) for injectable suspension by a registered nurse at a time and place convenient for your eligible patients so they continue to receive the correct prescribed dose at the right time.*
Trained MAP nurses will prepare and administer the medication†
Receive a report after each patient administration
Administration is available on nights and weekends, and when patients are traveling within the continental United States
Patients can receive their treatment at their home or workplace, or at another convenient location of their choice
*The program does not replace your care or the authority of the prescribing physician. Patients still keep their regularly scheduled physician checkups. First dose must be administered by prescribing physician.
†Limitations apply. Available only for patients with private insurance. Program not available for patients with Medicare, Medicaid, or any other federal or state program. Program not available for residents of Massachusetts, Michigan, Minnesota, or Rhode Island.
RealSupport™
RealSupport™: Real information from real patients
The RealSupport™ program was developed to provide support and information to people who are receiving, or may be appropriate candidates for, Sandostatin LAR Depot. This program does not replace the information provided by health care professionals. It offers additional information from health care experts and other people who are receiving Sandostatin LAR Depot. For more information, visit the Sandostatin LAR Depot Facebook page at www.facebook.com/SandostatinLARDepot.
Sandostatin Immediate-Release Injection Sample Program
The Sandostatin Immediate-Release Injection Sample Program allows health care providers to request samples of Sandostatin® LAR Depot (octreotide acetate) Immediate-Release Injection to be delivered to their offices.
To receive a Sandostatin Immediate-Release Injection sample for your patients who have severe diarrhea and flushing associated with metastatic carcinoid tumors, talk to your Novartis representative.
For more information, contact Novartis.